Abstract Library

#4196 Metastatic potential and associated mortality in a Greek cοhort of 123 MEN1 patients

Introduction: Prevalence of distant stage disease and overall mortality rates vary considerably among patients with multiple endocrine neoplasia type 1 (MEN1).

Conference:

Presenting Author: Papadopoulou-Marketou N

Authors: Papadopoulou-Marketou N, Daskalakis K, Chondrogianni M, Tsoli M, Kaltsas G,

Keywords: MEN1, pancreatic neuroendocrine tumor, thymus cancer,

#4039 Long-term natural history of enterochromaffin-like cell (ECL) hyperplasia

Introduction: Enterochromaffin-like cell (ECL) hyperplasia in the context of autoimmune atrophic gastritis, over a period of time, can progress to gastric neuroendocrine tumors (g-NETs) type 1.

Conference:

Presenting Author:

Authors: Karapanagioti A, Panagaki M, Ioannidou K, Papadopoulou N, Kaltsas G,

Keywords: ECL hyperplasia, g-NET type 1, gastrin,

#3786 Overview of screening and surveillance practices for MEN1-related pancreatic neuroendocrine neoplasms in ENETS CoEs – An ENETS MEN1 Task Force Questionnaire Study

Introduction: The 2012 MEN1 Clinical Practice Guidelines were based on expert opinion with limited evidence, leaving room for interpretation and variation in practices.

Conference:

Presenting Author:

Authors: Pieterman C, Kaltsas G, Valk G, On Behalf of the Enets Men1 Task Force N,

Keywords: men1, screening, surveillance, PanNEN, ENETS CoE, Questionnaire,

#3500 HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs)

Introduction: LAN is a long-term treatment for NETs, delivered in a ready-to-use syringe by monthly, deep subcutaneous injection. LAN PSPs aim to assist patients receiving their treatment at home, reducing both travel burden and the current risk of COVID-19 exposure. Furthermore, after training patients on stable dose can administer LAN independently (self or non-healthcare professional), where approved.

Conference:

Presenting Author: Hernando J

Authors: Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A,

Keywords: neuroendocrine tumor, patient satisfaction, patient support programme, patient survey, lanreotide autogel,

#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3

Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Friend E, Gray D, Fernández Ortega P, McNamara M, Kaltsas G,

Keywords: research, neuroendocrine, insulinoma, gastrinoma, non-functioning, VIPoma, Glucagonoma, questionnaire, quality of life,